About
Galvani Bioelectronics is a bioelectronics research and development company based in Stevenage, United Kingdom. Established in November 2016 as a joint venture between GlaxoSmithKline (GSK) and Verily Life Sciences, the company focuses on creating implantable devices that treat chronic diseases by modulating electrical signals in nerves that control organ function. GSK holds a 55% equity interest, while Verily holds 45%, with a significant investment commitment to develop bioelectronic medicines. The company targets both immunomodulatory and non-immunomodulatory chronic conditions, including rheumatoid arthritis, multiple sclerosis, type 1 diabetes, and chronic obstructive pulmonary disease (COPD). Galvani Bioelectronics combines GSK’s life sciences expertise with Verily’s software and electronics capabilities to develop therapies that are safe, precise, and minimally invasive. In November 2021, the company marked a significant milestone with the successful implantation of one of its devices in a patient, advancing its mission to innovate in the field of bioelectronic medicine.
Technologies
Keywords
Company Information
-
Employees 42
-
Founded 2016
-
Annual Revenue $1300000
Location
Gunnels Wood Road, Stevenage, England, United Kingdom, SG1 2
